Not Yet RecruitingNot Applicable

CArdio-Reno- Hepato -MEtabolic Disease iN Chronic Heart Failure (CARMEN-CHF)

3,000 participantsStarted 2026-02

Plain-language summary

Study aims to investigate the incidence, associations and prognostic value of CRGM and its components: chronic kidney disease, type 2 diabetes, atherosclerotic cardiovascular diseases, and non-alcoholic fatty liver disease in patients with different phenotypes and severity of clinical manifestations of CHF.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years;
✓. A diagnosis that satisfies one of the following criteria:
✓. . NT-proBNP level \>200 pg/mL in sinus rhythm or \>600 pg/mL in AF/AT,
✓. . E/é \>13 at rest by tissue Doppler,
✓. . 13 ≥E/é \>9 + left atrial dilation (LAD) \>34 ml/m2 in sinus rhythm or \>40 ml/m2 in AF/AT,
✓. . 13 ≥E/é \>9 + TR velocity \>2.8 m/s or PASP \>35 mmHg at rest,
✓. . 13 ≥E/é \>9 + presence of left ventricular hypertrophy, defined as LVMI \>115 g/m2 in men and \>95 g/m2 in women, WCT \>0.42, OR B. Presence of 7-9 points on the H2FPEF scale; OR C. Positive diastolic stress test result confirming increased LV filling pressure (E/e'≥15, TR velocity \>3.4 m/s) 3. No intravenous therapy with diuretics, nitrates, vasopressors, or inotropes within 24 hours prior to inclusion; 4. Availability of results of all of the following tests, performed no earlier than in the previous 6 months prior to inclusion in the study:

What they're measuring

the proportion of patients with the presence ofCardio-Kidney-Metabolic (CKM) Syndrome its components and their combinations

Timeframe: From date of enrollment until the date of first documented progression assessed up to 24 months

the proportion of patients with the presence ofCardio-Kidney-Metabolic (CKM) Syndrome its components and their combinations

Timeframe: From date of enrollment until the date of first documented occurrence assessed up to 24 months

Trial details

NCT IDNCT07380828

SponsorRussian Scientific Medical Society of Therapists

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2029-04

Contact for this trial

Anjela E Soloveva, Phd

+7 915 376 6940 anzhela.solovieva@gmail.com

View on ClinicalTrials.gov More Heart Failure trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years;
✓. A diagnosis that satisfies one of the following criteria:
✓. . NT-proBNP level \>200 pg/mL in sinus rhythm or \>600 pg/mL in AF/AT,
✓. . E/é \>13 at rest by tissue Doppler,
✓. . 13 ≥E/é \>9 + left atrial dilation (LAD) \>34 ml/m2 in sinus rhythm or \>40 ml/m2 in AF/AT,
✓. . 13 ≥E/é \>9 + TR velocity \>2.8 m/s or PASP \>35 mmHg at rest,
✓. . 13 ≥E/é \>9 + presence of left ventricular hypertrophy, defined as LVMI \>115 g/m2 in men and \>95 g/m2 in women, WCT \>0.42, OR B. Presence of 7-9 points on the H2FPEF scale; OR C. Positive diastolic stress test result confirming increased LV filling pressure (E/e'≥15, TR velocity \>3.4 m/s) 3. No intravenous therapy with diuretics, nitrates, vasopressors, or inotropes within 24 hours prior to inclusion; 4. Availability of results of all of the following tests, performed no earlier than in the previous 6 months prior to inclusion in the study:

What they're measuring

the proportion of patients with the presence ofCardio-Kidney-Metabolic (CKM) Syndrome its components and their combinations

Timeframe: From date of enrollment until the date of first documented progression assessed up to 24 months

the proportion of patients with the presence ofCardio-Kidney-Metabolic (CKM) Syndrome its components and their combinations

Timeframe: From date of enrollment until the date of first documented occurrence assessed up to 24 months